7 results about "Cardiac infarction" patented technology

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

The present invention provides methods for determining whether a subject suspected of having myocardial infarction is experiencing type I myocardial infarction or type II myocardial infarction. In particular, systems and methods are provided for processing the gender, age, and cardiac troponin concentration of a subject, as well as the galectin-3 (Gal-3) concentration of a subject, employing probability scoring based on a decision tree algorithm.

The invention discloses an asymptomatic myocardial infarction prediction method and related equipment based on a transferable space-time mask Transformer, and the method comprises the steps: carrying out the space-time mask modeling and model self-supervision pre-training of an electrocardiogram feature sequence constructed based on electrocardiogram data, and obtaining a pre-trained electrocardiogram feature extractor; carrying out migration fine tuning on the pre-trained electrocardiogram feature extractor by utilizing the small sample data set, and constructing a target electrocardiogram feature extractor for identifying the asymptomatic myocardial infarction; the method comprises the following steps: extracting electrocardiogram feature representation of a target object through a target electrocardiogram feature extractor, performing feature extraction and modeling on cardiac magnetic resonance imaging and clinical structural data of the target object based on a feature extraction module, and performing adaptive fusion on multi-modal features; and finally, generating an asymptomatic myocardial infarction risk prediction result based on the fusion features. The method can realize early accurate prediction of the asymptomatic myocardial infarction, and can be widely applied to the technical field of artificial intelligence.

The application discloses application of Piancizhu in preparation of a medicine for preventing and / or treating myocardial infarction. The application first discovers that Piancizhu can play an anti-cardiac ischemic injury role by improving heart function of a mouse model of left anterior descending branch stenosis of coronary artery, inhibiting inflammation levels of a heart, peripheral blood and bone marrow after cardiac infarction, reducing a myocardial infarction area and improving cardiac function disorder. Therefore, the application provides a scientific basis for increasing a clinical treatment indication of Piancizhu in acute myocardial infarction, simultaneously provides a new drug selection for clinical treatment of an acute cardiac infarction patient due to a good anti-inflammatory effect, and has a good application prospect.

The present invention relates to small molecule stimulators of steroid receptor coactivation-3 and methods of their use as cardiac protective agents and / or revascularization agents. Small molecule stimulators of steroid receptor co-activator-3 (SRC-3) and methods of their use as cardiac protective agents are provided. The small molecule stimulant can be used for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds may also be used to prevent cardiac hypertrophy and collagen deposition and to improve post-cardiac infarction function.

The invention discloses a novel application of DAT and bacteria for producing DAT. The application refers to application of DAT and bacteria generating DAT in preparation of drugs for preventing and / or treating myocardial ischemia / reperfusion injury. Prevention and / or treatment of myocardial ischemia / reperfusion injury are embodied in the following aspects: 1) heart injury after myocardial ischemia / reperfusion is relieved; 2) the apoptosis proportion of myocardial cells is reduced; 3) promotion of myocardial cell survival; 4) inhibiting cardiac fibrosis; 5) the area of cardiac infarction is reduced; and 6) inhibiting heart remodeling. Experimental results show that the pathological influence of ischemia / reperfusion injury of mice can be relieved by orally taking DAT or bacteria producing DAT, and the discovery provides a new thought and theoretical basis for development of DAT drugs and related bacteria.

The invention belongs to the technical field of cardiovascular disease treatment medicines, and particularly relates to application of ligustilide in preparation of a medicine for relieving inflammatory response after myocardial ischemia. According to the application disclosed by the invention, research finds that ligustilide can be used for remarkably inhibiting the level of S100A9 in serum, remarkably inhibiting expression of S100A9 mRNA and protein in a cardiac infarction region and expression of S100A9 in neutrophil for the first time, so that release of inflammatory factors and chemotactic factors can be effectively reduced, and occurrence of myocardial tissue inflammatory response is prevented or inflammatory response caused by myocardial ischemia is relieved; the compound can inhibit MI mouse infarction region neutrophil and mononuclear cell infiltration, and inhibit formation of NETs after MI and expression and activation of NLRP3 inflammasome, so that inflammatory response after MI can be relieved, and myocardial tissue can be protected. The application range of ligustilide in cardiovascular diseases is expanded, and a new drug choice is provided for prevention and treatment of inflammatory response after myocardial ischemia.